A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Clinical trial NCT06406465 · RECRUITING

Trial details

NCT number: NCT06406465
Sponsor: National Cancer Institute (NCI)
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Carcinoma, Neuroendocrine Tumor, Neuroendocrine Tumors, Neuroendocrine Neuroendocrine; Carcinoma Small Cell; Receptors

Start date: 2026-08-23
Primary completion: 2027-07-30
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.